查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1930053

自閉症譜系障礙治療市場規模、佔有率、成長及全球產業分析：按類型、應用和地區劃分的洞察，以及2025年至2034年的預測

Autism Spectrum Disorder Treatment Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2025-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 166 Pages | 商品交期: 請詢問到貨日

價格

自閉症譜系障礙 (ASD) 治療市場成長驅動因素

預計2025年全球自閉症譜系障礙 (ASD) 治療市場規模將達到85.5億美元，2026年將成長至92.1億美元，到2034年將達到186.8億美元，2026年至2034年的複合年增長率 (CAGR) 為9.23%。北美地區在2025年將以5.08%的市佔率領先，這主要得益於盛行率的上升、公眾意識的提高以及對溝通和行為療法投入的增加。

自閉症譜系障礙 (ASD) 是一種複雜的神經發育障礙，其特徵是持續的溝通和社交互動障礙，以及受限或重複的行為模式。市場成長的驅動因素包括 ASD 盛行率的不斷上升，尤其是在兒童群體中，以及對有效治療的持續未滿足的需求。根據美國疾病管制與預防中心 (CDC) 2025 年 5 月發布的一份報告，美國大約每 31 名 8 歲兒童中就有 1 名將被診斷出患有 ASD，這凸顯了對專業治療護理服務日益增長的需求。

市場驅動因素

推動市場成長的關鍵因素包括 ASD 盛行率的上升、早產兒存活率的提高、晚育以及懷孕期間接觸某些藥物和毒素等環境風險因素。護理人員和醫療保健專業人員對 ASD 的認識不斷提高，以及公共和私人保險對 ASD 覆蓋的支持，正在促進治療方法的普及，尤其是在北美地區。

市場限制因子

某些地區專科醫療資源有限、臨床醫生短缺以及漫長的候診名單限制了市場成長。症狀嚴重程度的差異、治療反應的差異以及嚴格的藥物審批監管流程進一步限制了市場擴張。一些地區缺乏核准藥物，促使人們更加依賴溝通和行為療法，但這些療法並非人人都能獲得。

市場機會

來自私募股權公司和醫療保健公司的投資正在創造巨大的成長機會。雖然自閉症譜系障礙治療市場仍未充分滿足，但應用行為分析 (ABA) 等療法的有效性正在推動投資和擴張。例如，Tenex Capital Management 於 2024 年 6 月收購了 Behavioral Innovations，這表明該公司持續致力於整合分散的市場並提高服務效率。

市場趨勢

新興趨勢包括引進新的介入和教育計畫。這些療法結合了行為療法、心理療法、教育療法和藥物療法，旨在提高患者的獨立性和生活品質。人工智慧和技術療法也日益受到關注，它們利用機器學習、虛擬實境 (VR) 和擴增實境 (AR) 平台來提高診斷準確性、客製化干預措施並提升治療效率。

細分市場分析

依治療類型劃分：溝通行為療法在2026年佔市場主導地位，市佔率高達74.75%。這主要歸功於其已被證實的有效性和較高的普及率，而藥物療法的應用範圍則較為有限。應用行為分析 (ABA) 療法仍然是主要的成長驅動力，其服務提供者正在全球擴展其特許經營模式。藥物治療，包括興奮劑、選擇性血清素再攝取抑制劑（SSRI）、抗精神病藥物和安眠藥，預計將隨著製藥公司加大研發投入而成長。

按類型劃分：自閉症譜系障礙（ASD）細分市場預計將在2026年佔50.14%的市場佔有率，成為市場主導，這主要得益於其高患病率、政府項目以及應用行為分析（ABA）療法服務的擴展。廣泛性發展障礙（PDD）佔第二大市場佔有率，而亞斯伯格症和其他ASD亞型由於臨床投入有限，預計成長速度將放緩。

區域展望

北美地區預計將在2025年以50.8億美元的收入引領市場，其主導地位將得益於高患病率、不斷擴大的治療選擇以及保險覆蓋範圍。預計到2026年，美國市場規模將達到51.1億美元，主要得益於ABA療法特許經營機構的推動，例如位於德克薩斯州奧斯汀的Success on the Spectrum。

到2025年，歐洲將佔第二大市場佔有率，預計到2026年，英國和德國的市場規模將分別達到2.1億美元和3.7億美元，這主要歸功於自閉症譜系障礙（ASD）患病率的上升和新型藥物療法的出現。亞太地區預計將實現最高的成長率，預計到2026年，日本、中國和印度的市場規模將分別達到4.2億美元、4億美元和1.6億美元。這一增長主要得益於政府措施、宣傳活動以及診斷率的提高。另一方面，由於醫療保健服務體系和政府支持方面的限制，拉丁美洲以及中東和非洲地區的成長速度預計將較為緩慢。

本報告詳細概述了自閉症譜系障礙治療市場，包括市場驅動因素、限制因素、趨勢、按治療類型劃分的市場細分、區域分析、競爭格局、行業趨勢和經濟成本考量。報告還重點關注監管框架、報銷方案以及新型技術驅動療法對市場趨勢的影響。

市場擴張的驅動因素包括自閉症譜系障礙盛行率的上升、照顧者和醫療保健提供者意識的提高，以及對有效治療（尤其是兒童治療）的持續未滿足的需求。溝通和行為療法，特別是應用行為分析（ABA），因其已被證實的有效性和廣泛的應用，在治療領域中佔主導地位。由於製藥業研發投入的增加和新藥臨床試驗的增多，藥物療法正在逐步發展。

目錄

第一章：引言

第二章：摘要整理

第三章：市場動態

  • 市場驅動因素
  • 市場限制因素
  • 市場機遇
  • 市場趨勢

第四章：關鍵考慮因素

  • 主要國家/地區自閉症盛行率（2025 年）
  • 主要產業趨勢（併購、合作等）
  • 主要國家/地區監管框架
  • 主要國家/地區自閉症譜系障礙治療的全球報銷和經濟負擔
  • COVID-19 的影響市場
  • ABA 產業的特許經營模式
  • 從藥物治療過渡到行為療法：聚焦 ABA 療法

第五章 全球自閉症譜系障礙治療市場分析、洞察與預測 (2021-2034)

  • 市場分析、洞察與預測 - 按治療類型劃分
    • 溝通與行為療法
      • 應用行為分析 (ABA)
      • 言語療法
      • 職業療法
      • 其他
    • 藥物療法
      • 抗精神病藥物
      • 選擇性血清素再攝取抑制劑 (SSRI)
      • 興奮劑
      • 安眠藥
      • 其他
    • 市場分析、洞察與預測 - 按類型劃分
      • 自閉症譜系障礙
      • 亞斯伯格症
      • 廣泛性發展障礙
      • 其他
    • 市場分析、洞察與預測 - 按地區劃分
      • 北美
      • 歐洲
      • 亞太地區
      • 拉丁美洲
      • 中東和非洲

第六章：北美自閉症譜系障礙治療市場分析、洞察與預測（2021-2034）

  • 依國家劃分
    • 美國
    • 加拿大

第七章：歐洲自閉症譜系障礙治療市場分析、洞察與預測（2021-2034）

  • 依國家/地區
    • 英國
    • 德國
    • 法國
    • 西班牙
    • 義大利
    • 斯堪的納維亞半島
    • 歐洲其他地區

第八章：亞太地區自閉症譜系障礙治療市場分析、洞察與預測（2021-2034）

  • 依國家劃分
    • 日本
    • 中國
    • 印度
    • 澳大利亞
    • 東南亞
    • 亞太其他地區

第九章：拉丁美洲自閉症譜系障礙治療市場分析、洞察與預測（2021-2034）

  • 依國家/地區
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地區

第十章 中東與非洲自閉症譜系障礙治療市場分析、洞察與預測（2021-2034）

  • 依國家劃分
    • 海灣合作委員會 (GCC)
    • 南非
    • 中東和非洲其他地區

第十一章 競爭分析

  • 全球市佔率分析（2025）
  • 公司簡介
    • Hopebridge, LLC.
    • 自閉症及相關障礙中心
    • 大塚控股株式會社
    • 輝瑞公司
    • 行為創新公司
    • 應用行為顧問公司
    • BlueSprig
    • 禮來公司
    • 成功譜系
    • 阿斯特捷利康
    • 強生服務公司
Product Code: FBI108573

Growth Factors of autism spectrum disorder (ASD) treatment Market

The global autism spectrum disorder (ASD) treatment market was valued at USD 8.55 billion in 2025 and is projected to grow to USD 9.21 billion in 2026, reaching USD 18.68 billion by 2034, representing a CAGR of 9.23% from 2026 to 2034. North America dominated the market in 2025 with a 5.08% share, driven by rising prevalence, growing awareness, and increasing investment in communication and behavioral therapies.

ASD is a complex neurodevelopmental disorder characterized by persistent deficits in communication and social interaction, alongside restricted or repetitive patterns of behavior. Market growth is being fueled by the rising prevalence of ASD, particularly in children, and the persistent unmet need for effective therapies. According to the CDC in May 2025, approximately 1 in 31 children aged 8 in the U.S. are diagnosed with ASD, highlighting the increasing demand for specialized treatment and care services.

Market Drivers

Key factors driving market growth include rising prevalence of ASD, higher survival rates of premature babies, late-age pregnancies, and exposure to environmental risk factors such as certain drugs or toxins during pregnancy. Increased awareness among caregivers and healthcare providers, along with private and public support for insurance coverage, is boosting the adoption of treatment options, particularly in North America.

Market Restraints

Limited access to specialized care in certain regions, clinician shortages, and long waitlists restrict market growth. Variability in symptom severity, diverse responses to therapies, and stringent regulatory pathways for drug approvals further constrain market expansion. The lack of approved drugs in some regions emphasizes the reliance on communication and behavioral therapies, which may not be uniformly accessible.

Market Opportunities

Investments from private equity firms and healthcare companies are creating significant growth opportunities. ASD treatment remains an underserved market, but the effectiveness of therapies such as Applied Behavior Analysis (ABA) has attracted investment and expansion. For instance, in June 2024, Tenex Capital Management acquired Behavioral Innovations, demonstrating the ongoing interest in consolidating fragmented markets and increasing service efficiency.

Market Trends

Emerging trends include the introduction of novel interventional and educational programs, combining behavioral, psychological, educational, and pharmacological therapies to enhance patient independence and quality of life. AI and technology-based therapies are gaining traction, including machine learning, virtual reality, and augmented reality platforms to improve diagnosis, customize interventions, and enhance treatment efficiency.

Segmentation Analysis

By Treatment Type: Communication and behavioral therapies dominated the market in 2026 with a 74.75% share, due to their proven effectiveness and higher adoption compared to limited drug therapies. ABA therapy remains a key driver of growth, with providers expanding franchise models globally. Drug therapies, including stimulants, SSRIs, antipsychotics, and sleep medications, are expected to grow as pharmaceutical companies intensify R&D efforts.

By Type: The autistic disorder segment led the market in 2026 with a 50.14% share, supported by high prevalence, government programs, and expansion of ABA therapy services. Pervasive developmental disorder (PDD) holds the second-largest share, while Asperger syndrome and other ASD types are projected to grow at slower rates due to limited clinical initiatives.

Regional Outlook

North America led the market in 2025 with USD 5.08 billion in revenue, maintaining dominance due to high prevalence, expanded therapy options, and insurance coverage support. The U.S. market is projected to reach USD 5.11 billion by 2026, bolstered by ABA therapy franchises such as Success on the Spectrum in Austin, Texas.

Europe held the second-largest share in 2025, with the UK and Germany projected to reach USD 0.21 billion and USD 0.37 billion by 2026, driven by rising ASD prevalence and new drug therapies. Asia Pacific is expected to grow at the fastest rate, with Japan, China, and India projected to reach USD 0.42 billion, USD 0.4 billion, and USD 0.16 billion respectively by 2026, supported by government policies, awareness programs, and increased diagnosis. Latin America and the Middle East & Africa are growing at a slower pace due to limited healthcare provisions and government support.

Competitive Landscape

The ASD treatment market is highly fragmented, with communication & behavioral therapy providers such as BlueSprig, Action Behavioral Centers (ABC), ACES ABA, Centria Autism, Hopebridge, and SUCCESS ON THE SPECTRUM dominating the segment. Leading pharmaceutical companies in drug therapies include Otsuka Pharmaceuticals, AstraZeneca, Pfizer, Eli Lilly, and Johnson & Johnson. Key strategies involve expansion, acquisitions, collaborations, and R&D initiatives, such as BlueSprig's acquisition of Trumpet Behavioral Health in October 2023 and ongoing clinical trials for novel ASD drugs.

Report Coverage

The report offers a detailed overview of the ASD treatment market, including market drivers, restraints, trends, segmentation by type and therapy, regional analysis, competitive landscape, industry developments, and economic cost considerations. Additionally, it highlights regulatory frameworks, reimbursement scenarios, and the impact of emerging technology-driven therapies on the market trajectory.

Conclusion

The global autism spectrum disorder treatment market is poised for strong growth, with a valuation of USD 8.55 billion in 2025, projected to reach USD 9.21 billion in 2026, and forecasted to hit USD 18.68 billion by 2034, representing a CAGR of 9.23% during the period 2026-2034. North America remains the largest market, supported by high prevalence rates, widespread adoption of communication and behavioral therapies, insurance coverage, and ongoing investments in innovative treatment solutions.

Market expansion is driven by the rising prevalence of ASD, increased awareness among caregivers and healthcare providers, and persistent unmet needs for effective therapies, particularly in children. Communication and behavioral therapies, especially Applied Behavior Analysis (ABA), dominate the treatment landscape due to their proven effectiveness and widespread adoption. Drug therapies are gradually expanding with growing pharmaceutical R&D and clinical trials for novel medications.

Segmentation By Treatment Type

  • Communication & Behavioral Therapies
    • Applied Behavior Analysis (ABA)
    • Speech & Language Therapy
    • Occupational Therapy
    • Others
  • Drug Therapies
    • Antipsychotic Drugs
    • SSRIs/Antidepressants
    • Stimulants
    • Sleep Medications
    • Others

By Type

  • Autistic Disorder
  • Asperger Syndrome
  • Pervasive Developmental Disorder (PDD)
  • Others

By Geography

  • North America (By Treatment Type, Type, and Country)
  • U.S.
  • Canada
  • Europe (By Treatment Type, Type, and Country/Sub-Region)
  • U.K.
  • Germany
  • France
  • Italy
  • Spain
  • Scandinavia
  • Rest of Europe
  • Asia Pacific (By Treatment Type, Type, and Country/Sub-Region)
  • China
  • Japan
  • India
  • Australia
  • Southeast Asia
  • Rest of Asia Pacific
  • Latin America (By Treatment Type, Type, and Country/Sub-Region)
  • Brazil
  • Mexico
  • Rest of Latin America
  • The Middle East & Africa (By Treatment Type, Type, and Country/Sub-Region)
  • GCC Countries
  • South Africa
  • Rest of the Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Prevalence of Autism, By Key Countries, 2025
  • 4.2. Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)
  • 4.3. Regolatory Framework by Key Countries/Regions
  • 4.4. Global Reimbursement Scenario and Economic Cost Burden for the Treatment of Autism Spectrum Disorder by Key Countries/Region
  • 4.5. Impact of COVID-19 on the Market
  • 4.6. A Franchise Model in ABA Industry
  • 4.7. Shift from Pharmacological Interventions to Behavioral Therapies: Focus on ABA Therapy

5. Global Autism Spectrum Disorder Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Treatment Type
    • 5.1.1. Communication & Behavioral Therapies
      • 5.1.1.1. Applied Behavior Analysis (ABA)
      • 5.1.1.2. Speech & Language Therapy
      • 5.1.1.3. Occupational Therapy
      • 5.1.1.4. Others
    • 5.1.2. Drug Therapy
      • 5.1.2.1. Antipsychotic Drugs
      • 5.1.2.2. SSRIS
      • 5.1.2.3. Stimolants
      • 5.1.2.4. Sleep Medications
      • 5.1.2.5. Others
    • 5.1.3. Market Analysis, Insights and Forecast - By Type
      • 5.1.3.1. Autistic Disorder
      • 5.1.3.2. Asperger Syndrome
      • 5.1.3.3. Pervasive Developmental Disorder
      • 5.1.3.4. Others
    • 5.1.4. Market Analysis, Insights and Forecast - By Region
      • 5.1.4.1. North America
      • 5.1.4.2. Europe
      • 5.1.4.3. Asia Pacific
      • 5.1.4.4. Latin America
      • 5.1.4.5. Middle East & Africa

6. North America Autism Spectrum Disorder Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Treatment Type
    • 6.1.1. Communication & Behavioral Therapies
      • 6.1.1.1. Applied Behavior Analysis (ABA)
      • 6.1.1.2. Speech & Language Therapy
      • 6.1.1.3. Occupational Therapy
      • 6.1.1.4. Others
    • 6.1.2. Drug Therapy
      • 6.1.2.1. Antipsychotic Drugs
      • 6.1.2.2. SSRIS
      • 6.1.2.3. Stimolants
      • 6.1.2.4. Sleep Medications
      • 6.1.2.5. Others
    • 6.1.3. Market Analysis, Insights and Forecast - By Type
      • 6.1.3.1. Autistic Disorder
      • 6.1.3.2. Asperger Syndrome
      • 6.1.3.3. Pervasive Developmental Disorder
      • 6.1.3.4. Others
    • 6.1.4. Market Analysis, Insights and Forecast - By Country
      • 6.1.4.1. U.S.
      • 6.1.4.2. Canada

7. Europe Autism Spectrum Disorder Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Treatment Type
    • 7.1.1. Communication & Behavioral Therapies
      • 7.1.1.1. Applied Behavior Analysis (ABA)
      • 7.1.1.2. Speech & Language Therapy
      • 7.1.1.3. Occupational Therapy
      • 7.1.1.4. Others
    • 7.1.2. Drug Therapy
      • 7.1.2.1. Antipsychotic Drugs
      • 7.1.2.2. SSRIS
      • 7.1.2.3. Stimolants
      • 7.1.2.4. Sleep Medications
      • 7.1.2.5. Others
    • 7.1.3. Market Analysis, Insights and Forecast - By Type
      • 7.1.3.1. Autistic Disorder
      • 7.1.3.2. Asperger Syndrome
      • 7.1.3.3. Pervasive Developmental Disorder
      • 7.1.3.4. Others
    • 7.1.4. Market Analysis, Insights and Forecast - By Country/Sub-region
      • 7.1.4.1. U.K.
      • 7.1.4.2. Germany
      • 7.1.4.3. France
      • 7.1.4.4. Spain
      • 7.1.4.5. Italy
      • 7.1.4.6. Scandinavia
      • 7.1.4.7. Rest of Europe

8. Asia Pacific Autism Spectrum Disorder Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Treatment Type
    • 8.1.1. Communication & Behavioral Therapies
      • 8.1.1.1. Applied Behavior Analysis (ABA)
      • 8.1.1.2. Speech & Language Therapy
      • 8.1.1.3. Occupational Therapy
      • 8.1.1.4. Others
    • 8.1.2. Drug Therapy
      • 8.1.2.1. Antipsychotic Drugs
      • 8.1.2.2. SSRIS
      • 8.1.2.3. Stimolants
      • 8.1.2.4. Sleep Medications
      • 8.1.2.5. Others
    • 8.1.3. Market Analysis, Insights and Forecast - By Type
      • 8.1.3.1. Autistic Disorder
      • 8.1.3.2. Asperger Syndrome
      • 8.1.3.3. Pervasive Developmental Disorder
      • 8.1.3.4. Others
    • 8.1.4. Market Analysis, Insights and Forecast - By Country/Sub-region
      • 8.1.4.1. Japan
      • 8.1.4.2. China
      • 8.1.4.3. India
      • 8.1.4.4. Australia
      • 8.1.4.5. Southeast Asia
      • 8.1.4.6. Rest of Asia Pacific

9. Latin America Autism Spectrum Disorder Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Treatment Type
    • 9.1.1. Communication & Behavioral Therapies
      • 9.1.1.1. Applied Behavior Analysis (ABA)
      • 9.1.1.2. Speech & Language Therapy
      • 9.1.1.3. Occupational Therapy
      • 9.1.1.4. Others
    • 9.1.2. Drug Therapy
      • 9.1.2.1. Antipsychotic Drugs
      • 9.1.2.2. SSRIS
      • 9.1.2.3. Stimolants
      • 9.1.2.4. Sleep Medications
      • 9.1.2.5. Others
    • 9.1.3. Market Analysis, Insights and Forecast - By Type
      • 9.1.3.1. Autistic Disorder
      • 9.1.3.2. Asperger Syndrome
      • 9.1.3.3. Pervasive Developmental Disorder
      • 9.1.3.4. Others
    • 9.1.4. Market Analysis, Insights and Forecast - By Country/Sub-region
      • 9.1.4.1. Brazil
      • 9.1.4.2. Mexico
      • 9.1.4.3. Rest of Latin America

10. Middle East & Africa Autism Spectrum Disorder Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Treatment Type
    • 10.1.1. Communication & Behavioral Therapies
      • 10.1.1.1. Applied Behavior Analysis (ABA)
      • 10.1.1.2. Speech & Language Therapy
      • 10.1.1.3. Occupational Therapy
      • 10.1.1.4. Others
    • 10.1.2. Drug Therapy
      • 10.1.2.1. Antipsychotic Drugs
      • 10.1.2.2. SSRIS
      • 10.1.2.3. Stimolants
      • 10.1.2.4. Sleep Medications
      • 10.1.2.5. Others
    • 10.1.3. Market Analysis, Insights and Forecast - By Type
      • 10.1.3.1. Autistic Disorder
      • 10.1.3.2. Asperger Syndrome
      • 10.1.3.3. Pervasive Developmental Disorder
      • 10.1.3.4. Others
    • 10.1.4. Market Analysis, Insights and Forecast - By Country/Sub-region
      • 10.1.4.1. GCC Countries
      • 10.1.4.2. South Africa
      • 10.1.4.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Company Profiles
    • 11.2.1. Hopebridge, LLC.
      • 11.2.1.1. Overview
      • 11.2.1.2. Services
      • 11.2.1.3. SWOT Analysis
      • 11.2.1.4. Recent Developments
      • 11.2.1.5. Strategies
      • 11.2.1.6. Financials (Based on Availability)
    • 11.2.2. Center for Autism and Related Disorders
      • 11.2.2.1. Overview
      • 11.2.2.2. Services
      • 11.2.2.3. SWOT Analysis
      • 11.2.2.4. Recent Developments
      • 11.2.2.5. Strategies
      • 11.2.2.6. Financials (Based on Availability)
    • 11.2.3. Otsuka Holdings Co., Ltd.
      • 11.2.3.1. Overview
      • 11.2.3.2. Services
      • 11.2.3.3. SWOT Analysis
      • 11.2.3.4. Recent Developments
      • 11.2.3.5. Strategies
      • 11.2.3.6. Financials (Based on Availability)
    • 11.2.4. Pfizer Inc.
      • 11.2.4.1. Overview
      • 11.2.4.2. Services
      • 11.2.4.3. SWOT Analysis
      • 11.2.4.4. Recent Developments
      • 11.2.4.5. Strategies
      • 11.2.4.6. Financials (Based on Availability)
    • 11.2.5. Behavioral Innovations
      • 11.2.5.1. Overview
      • 11.2.5.2. Services
      • 11.2.5.3. SWOT Analysis
      • 11.2.5.4. Recent Developments
      • 11.2.5.5. Strategies
      • 11.2.5.6. Financials (Based on Availability)
    • 11.2.6. Applied Behavior Consoltants, Inc.
      • 11.2.6.1. Overview
      • 11.2.6.2. Services
      • 11.2.6.3. SWOT Analysis
      • 11.2.6.4. Recent Developments
      • 11.2.6.5. Strategies
      • 11.2.6.6. Financials (Based on Availability)
    • 11.2.7. BlueSprig
      • 11.2.7.1. Overview
      • 11.2.7.2. Services
      • 11.2.7.3. SWOT Analysis
      • 11.2.7.4. Recent Developments
      • 11.2.7.5. Strategies
      • 11.2.7.6. Financials (Based on Availability)
    • 11.2.8. Eli Lilly and Company
      • 11.2.8.1. Overview
      • 11.2.8.2. Services
      • 11.2.8.3. SWOT Analysis
      • 11.2.8.4. Recent Developments
      • 11.2.8.5. Strategies
      • 11.2.8.6. Financials (Based on Availability)
    • 11.2.9. SUCCESS ON THE SPECTRUM
      • 11.2.9.1. Overview
      • 11.2.9.2. Services
      • 11.2.9.3. SWOT Analysis
      • 11.2.9.4. Recent Developments
      • 11.2.9.5. Strategies
      • 11.2.9.6. Financials (Based on Availability)
    • 11.2.10. AstraZeneca
      • 11.2.10.1. Overview
      • 11.2.10.2. Services
      • 11.2.10.3. SWOT Analysis
      • 11.2.10.4. Recent Developments
      • 11.2.10.5. Strategies
      • 11.2.10.6. Financials (Based on Availability)
    • 11.2.11. Johnson & Johnson Services, Inc.
      • 11.2.11.1. Overview
      • 11.2.11.2. Services
      • 11.2.11.3. SWOT Analysis
      • 11.2.11.4. Recent Developments
      • 11.2.11.5. Strategies
      • 11.2.11.6. Financials (Based on Availability)

List of Tables

  • Table 1: Global Autism Spectrum Disorder Treatment Market Revenue (USD billion) Forecast, By Treatment Type, 2021-2034
  • Table 2: Global Autism Spectrum Disorder Treatment Market Revenue (USD billion) Forecast, By Communication & Behavioral Therapies, 2021-2034
  • Table 3: Global Autism Spectrum Disorder Treatment Market Revenue (USD billion) Forecast, By Drug Therapies, 2021-2034
  • Table 4: Global Autism Spectrum Disorder Treatment Market Revenue (USD billion) Forecast, By Type, 2021-2034
  • Table 5: Global Autism Spectrum Disorder Treatment Market Revenue (USD billion) Forecast, by Region, 2021-2034
  • Table 6: North America Autism Spectrum Disorder Treatment Market Revenue (USD billion) Forecast, By Treatment Type, 2021-2034
  • Table 7: North America Autism Spectrum Disorder Treatment Market Revenue (USD billion) Forecast, By Communication & Behavioral Therapies, 2021-2034
  • Table 8: North America Autism Spectrum Disorder Treatment Market Revenue (USD billion) Forecast, By Drug Therapies, 2021-2034
  • Table 9: North America Autism Spectrum Disorder Treatment Market Revenue (USD billion) Forecast, By Type, 2021-2034
  • Table 10: North America Autism Spectrum Disorder Treatment Market Revenue (USD billion) Forecast, By Country, 2021-2034
  • Table 11: Europe Autism Spectrum Disorder Treatment Market Revenue (USD billion) Forecast, By Treatment Type, 2021-2034
  • Table 12: Europe Autism Spectrum Disorder Treatment Market Revenue (USD billion) Forecast, By Communication & Behavioral Therapies, 2021-2034
  • Table 13: Europe Autism Spectrum Disorder Treatment Market Revenue (USD billion) Forecast, By Drug Therapies, 2021-2034
  • Table 14: Europe Autism Spectrum Disorder Treatment Market Revenue (USD billion) Forecast, By Type, 2021-2034
  • Table 15: Europe Autism Spectrum Disorder Treatment Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 16: Asia Pacific Autism Spectrum Disorder Treatment Market Revenue (USD billion) Forecast, By Treatment Type, 2021-2034
  • Table 17: Asia Pacific Autism Spectrum Disorder Treatment Market Revenue (USD billion) Forecast, By Communication & Behavioral Therapies, 2021-2034
  • Table 18: Asia Pacific Autism Spectrum Disorder Treatment Market Revenue (USD billion) Forecast, By Drug Therapies, 2021-2034
  • Table 19: Asia Pacific Autism Spectrum Disorder Treatment Market Revenue (USD billion) Forecast, By Type, 2021-2034
  • Table 20: Asia Pacific Autism Spectrum Disorder Treatment Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 21: Latin America Autism Spectrum Disorder Treatment Market Revenue (USD billion) Forecast, By Treatment Type, 2021-2034
  • Table 22: Latin America Autism Spectrum Disorder Treatment Market Revenue (USD billion) Forecast, By Communication & Behavioral Therapies, 2021-2034
  • Table 23: Latin America Autism Spectrum Disorder Treatment Market Revenue (USD billion) Forecast, By Drug Therapies, 2021-2034
  • Table 24: Latin America Autism Spectrum Disorder Treatment Market Revenue (USD billion) Forecast, By Type, 2021-2034
  • Table 25: Latin America Autism Spectrum Disorder Treatment Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 26: Middle East & Africa Autism Spectrum Disorder Treatment Market Revenue (USD billion) Forecast, By Treatment Type, 2021-2034
  • Table 27: Middle East & Africa Autism Spectrum Disorder Treatment Market Revenue (USD billion) Forecast, By Communication & Behavioral Therapies, 2021-2034
  • Table 28: Middle East & Africa Autism Spectrum Disorder Treatment Market Revenue (USD billion) Forecast, By Drug Therapies, 2021-2034
  • Table 29: Middle East & Africa Autism Spectrum Disorder Treatment Market Revenue (USD billion) Forecast, By Type, 2021-2034
  • Table 30: Middle East & Africa Autism Spectrum Disorder Treatment Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034

List of Figures

  • Figure 1: Global Autism Spectrum Disorder Treatment Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
  • Figure 2: Global Autism Spectrum Disorder Treatment Market Value Share (%), By Treatment Type, 2025 & 2034
  • Figure 3: Global Autism Spectrum Disorder Treatment Market Value Share (%), By Type, 2025 & 2034
  • Figure 4: Global Autism Spectrum Disorder Treatment Market Value (USD billion), by Region, 2025 & 2034
  • Figure 5: North America Autism Spectrum Disorder Treatment Market Value (USD billion), By Treatment Type, 2025 & 2034
  • Figure 6: North America Autism Spectrum Disorder Treatment Market Value Share (%), By Treatment Type, 2025
  • Figure 7: North America Autism Spectrum Disorder Treatment Market Value (USD billion), By Type, 2025 & 2034
  • Figure 8: North America Autism Spectrum Disorder Treatment Market Value Share (%), By Type, 2025
  • Figure 9: North America Autism Spectrum Disorder Treatment Market Value (USD billion), By Country, 2025 & 2034
  • Figure 10: North America Autism Spectrum Disorder Treatment Market Value Share (%), By Country, 2025
  • Figure 11: Europe Autism Spectrum Disorder Treatment Market Value (USD billion), By Treatment Type, 2025 & 2034
  • Figure 12: Europe Autism Spectrum Disorder Treatment Market Value Share (%), By Treatment Type, 2025
  • Figure 13: Europe Autism Spectrum Disorder Treatment Market Value (USD billion), By Type, 2025 & 2034
  • Figure 14: Europe Autism Spectrum Disorder Treatment Market Value Share (%), By Type, 2025
  • Figure 15: Europe Autism Spectrum Disorder Treatment Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 16: Europe Autism Spectrum Disorder Treatment Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 17: Asia Pacific Autism Spectrum Disorder Treatment Market Value (USD billion), By Treatment Type, 2025 & 2034
  • Figure 18: Asia Pacific Autism Spectrum Disorder Treatment Market Value Share (%), By Treatment Type, 2025
  • Figure 19: Asia Pacific Autism Spectrum Disorder Treatment Market Value (USD billion), By Type, 2025 & 2034
  • Figure 20: Asia Pacific Autism Spectrum Disorder Treatment Market Value Share (%), By Type, 2025
  • Figure 21: Asia Pacific Autism Spectrum Disorder Treatment Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 22: Asia Pacific Autism Spectrum Disorder Treatment Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 23: Latin America Autism Spectrum Disorder Treatment Market Value (USD billion), By Treatment Type, 2025 & 2034
  • Figure 24: Latin America Autism Spectrum Disorder Treatment Market Value Share (%), By Treatment Type, 2025
  • Figure 25: Latin America Autism Spectrum Disorder Treatment Market Value (USD billion), By Type, 2025 & 2034
  • Figure 26: Latin America Autism Spectrum Disorder Treatment Market Value Share (%), By Type, 2025
  • Figure 27: Latin America Autism Spectrum Disorder Treatment Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 28: Latin America Autism Spectrum Disorder Treatment Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 29: Middle East & Africa Autism Spectrum Disorder Treatment Market Value (USD billion), By Treatment Type, 2025 & 2034
  • Figure 30: Middle East & Africa Autism Spectrum Disorder Treatment Market Value Share (%), By Treatment Type, 2025
  • Figure 31: Middle East & Africa Autism Spectrum Disorder Treatment Market Value (USD billion), By Type, 2025 & 2034
  • Figure 32: Middle East & Africa Autism Spectrum Disorder Treatment Market Value Share (%), By Type, 2025
  • Figure 33: Middle East & Africa Autism Spectrum Disorder Treatment Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 34: Middle East & Africa Autism Spectrum Disorder Treatment Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 35: Global Autism Spectrum Disorder Treatment Market Share (%), By Company, 2025